Surrey Heartlands

Joint Formulary & PAD

Hyaluronic acid - Osteoarthritis

You are here : Home > Formulary Search > Hyaluronic acid - Osteoarthritis

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Intra-articular injection
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
Restrictions / Comments :

Documentation

Evidence Review
Hyaluronic Acid in osteoarthritis - Evidence review - Dec 2010

PAD Profile

ChemicalSubstance :
Hyaluronic acid
Indication :
Osteoarthritis
Group Name :
Keywords :
Sodium hyaluronate, synovial fluid, synovial joint injections,
Brand Names Include :
Durolane, Euflexxa, Fermathron, Hyalgan, Orthovisc, Ostenil, Suplasyn, Synocrom, Synopsis, Hylan GF, Synvisc ONE, Monovisc, Orthovisc, Synolis,
Important Information :
ASPH rehumatology only - Ostenil, Viscoseal and Synvisc
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1

Other Indications

Below are listed other indications that Hyaluronic acid is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Osteoarthritis.

Committee Recommendations (1)

06 Jun 18 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Prescribing Clinical Network (PCN), during the update of the persistant non-malignant pain guidelines, does not recommend intra-articular hyaluronic acid injection in line with NICE guidance CG177. 

It may be suitable for individual patients for whom other pharmacological options have been intolerable or ineffective and who are unable to undergo surgery. Hyaluronic acid for these patients should be made available on an individual basis at the Acute Trust (this is not a Payment by Results Excluded drug and in individual cases GPs should not be asked to prescribe). (Discussed and agreed by PCN in January 2011)